Skip to main content
PMC home page
Cancer Science logoLink to Cancer Science
. 2005 Aug 19;94(6):548–556. doi: 10.1111/j.1349-7006.2003.tb01481.x

Immunological evaluation of CTL precursor‐oriented vaccines for advanced lung cancer patients

Takashi Mine 1,2,3, Rumi Gouhara 3, Naoya Hida 1, Nobue Imai 1, Kouichi Azuma 1, Touru Rikimaru 3, Kazuko Katagiri 1, Misa Nishikori 1, Aki Sukehiro 1, Masami Nakagawa 1, Akira Yamada 4, Hisamichi Aizawa 3, Kazuo Shirouzu 2, Kyogo Itoh 1, Hideaki Yamana 2
PMCID: PMC11160226  PMID: 12824881

Abstract

Recent clinical trials of peptide vaccine for cancer patients have rarely resulted in tumor regression. One of the reasons for this failure could be an insufficient induction of anti‐tumor responses in these regimens, in which peptide‐specific memory cytotoxic T lymphocytes (CTLs) were not measured prior to vaccination. We investigated in this study whether pre‐vaccination measurement of peptide‐specific CTLs can provide any advantages in lung cancer patients receiving peptide vaccination with regard to safety and immunological responses. Ten patients with advanced lung cancer received vaccination with peptides under a regimen of CTL precursor‐oriented vaccination, in which pre‐vaccination peripheral blood mononuclear cells (PBMCs) were at first screened for reactivity in vitro to each of 14 peptides, followed by in vivo administration of only the reactive peptides. Profiles of the vaccinated peptides varied markedly among the 10 patients. This regimen was generally well‐tolerated, although local skin reactions, diarrhea, and colitis were observed in 8, 2, and 1 patient, respectively. Increased CTL responses against the immunized peptides and tumor cells were observed in the post‐vaccination PBMCs from 4 of 8 and 3 of 10 patients tested, respectively. Peptide‐specific IgG became detectable in post‐vaccination sera in 4 of 10 patients tested, and these 4 patients had a long progression‐free survival. Furthermore, the median survival time of 9 patients with non‐small cell lung cancer was 668.0±164.2 days. These results encourage further development of CTL precursor‐oriented peptide vaccination for lung cancer patients.

References

  • 1. Van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643–7. [DOI] [PubMed] [Google Scholar]
  • 2. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, Appella E, Rosenberg SA. Identification of the immunodominant peptides of the MART‐1 human melanoma antigen recognized by the majority of HLA‐A2‐restricted tumor infiltrating lymphocytes. J Exp Med 1994; 180: 347–52. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA. Identification of a human melanoma antigen recognized by tumor‐infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994; 91: 6458–62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Brichard V, Van Pel A, Wolfel T, Wolfel C, De Plaen E, Lethe B, Coulie P, Boon T. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA‐A2 melanomas. J Exp Med 1993; 178: 489–95. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Robbins PF, El‐Gamil M, Li YF, Kawakami Y, Loftus D, Appella E, Rosenberg SA. A mutated beta‐catenin gene encodes a melanoma‐specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 1996; 183: 1185–92. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ. Breast and ovarian cancer‐specific cytotoxic T lymphocytes recognize the same HER2/neu‐derived peptide. Proc Natl Acad Sci USA 1995; 92: 432–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Fisk B, Blevins TL, Wharton JT, Ioannides CG. Identification of an immunodominant peptide of HER‐2/neu protooncogene recognized by ovarian tumor‐specific cytotoxic T lymphocyte lines. J Exp Med 1995; 181: 2109–17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Correale P, Walmsley K, Nieroda C, Zaremba S, Zhu M, Schlom J, Tsang KY. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate‐specific antigen. J Natl Cancer Inst 1997; 89: 293–300. [DOI] [PubMed] [Google Scholar]
  • 9. Correale P, Walmsley K, Zaremba S, Zhu M, Schlom J, Tsang KY. Generation of human cytolytic T lymphocyte lines directed against prostate‐specific antigen (PSA) employing a PSA oligoepitope peptide. J Immunol 1998; 161: 3186–94. [PubMed] [Google Scholar]
  • 10. Jager E, Gnjatic S, Nagata Y, Stockert E, Jager D, Karbach J, Neumann A, Rieckenberg J, Chen YT, Ritter G, Hoffman E, Arand M, Old LJ, Knuth A. Induction of primary NY‐ESO‐1 immunity: CD8+ T lymphocyte and antibody responses in peptide‐vaccinated patients with NY‐ESO‐1 + cancers. Proc Natl Acad Sci USA 2000; 97: 12198–203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Marchand M, van Baren N, Weynants P, Brichard V, Dreno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vanwijck R, Lienard D, Beauduin M, Dietrich PY, Russo V, Kerger J, Masucci G, Jager E, De Greve J, Atzpodien J, Brasseur F, Coulie PG, van der Bruggen P, Boon T. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLAAl. Int J Cancer 1999; 80: 219–30. [DOI] [PubMed] [Google Scholar]
  • 12. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4: 321–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Valmori D, Dutoit V, Rubio‐Godoy V, Chambaz C, Lienard D, Guillaume P, Romero P, Cerottini JC, Rimoldi D. Frequent cytolytic T‐cell responses to peptide MAGE‐A10(254–262) in melanoma. Cancer Res 2001; 61: 509–12. [PubMed] [Google Scholar]
  • 14. Gajewski TF, Fallarino F, Ashikari A, Sherman M. Immunization of HLAA2+ melanoma patients with MAGE‐3 or MelanA peptide‐pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin Cancer Res 2001; 7: 895s–901s. [PubMed] [Google Scholar]
  • 15. Gjertsen MK, Buanes T, Rosseland AR, Bakka A, Gladhaug I, Soreide O, Eriksen JA, Moller M, Baksaas I, Lothe RA, Saeterdal I, Gaudernack G. Intradermal ras peptide vaccination with granulocyte‐macrophage colony‐stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 2001; 92: 441–50. [DOI] [PubMed] [Google Scholar]
  • 16. Lau R, Wang F, Jeffery G, Marty V, Kuniyoshi J, Bade E, Ryback ME, Weber J. Phase I trial of intravenous peptide‐pulsed dendritic cells in patients with metastatic melanoma. J Immunother 2001; 24: 66–78. [DOI] [PubMed] [Google Scholar]
  • 17. Gohara R, Imai N, Rikimaru T, Yamada A, Hida N, Ichiki M, Kawamoto M, Matsunaga K, Ashihara J, Yano S, Tamura M, Ohkouchi S, Yamana H, Oizumi K, Itoh K. Phase 1 clinical study of cyclophilin B peptide vaccine for lung cancer patients. J Immunother 2002; 25: 439–44. [DOI] [PubMed] [Google Scholar]
  • 18. Miyagi Y, Imai N, Sasatomi T, Yamada A, Mine T, Katagiri K, Nakagawa M, Muto A, Okouchi S, Isomoto H, Shirouzu K, Yamana H, Itoh K. Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides. Clin Cancer Res 2001; 7: 3950–62. [PubMed] [Google Scholar]
  • 19. Hida N, Maeda Y, Katagiri K, Takasu H, Harada M, Itoh K. A simple culture protocol to detect peptide‐specific cytotoxic T lymphocyte precursors in the circulation. Cancer Immunol Immunother 2002; 51: 219–28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Suzuki N, Maeda Y, Tanaka S, Hida N, Mine T, Yamamoto K, Oka M, Itoh K. Detection of peptide‐specific cytotoxic T lymphocyte precursors used for specific immunotherapy of pancreatic cancer. Int J Cancer 2002; 98: 45–50. [DOI] [PubMed] [Google Scholar]
  • 21. Shichijo S, Nakao M, Imai Y, Takasu H, Kawamoto M, Niiya F, Yang D, Toh Y, Yamana H, Itoh K. A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med 1998; 187: 277–88. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Nakao M, Shichijo S, Imaizumi T, Inoue Y, Matsunaga K, Yamada A, Kikuchi M, Tsuda N, Ohta K, Takamori S, Yamana H, Fujita H, Itoh K. Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL. J Immunol 2000; 164: 2565–74. [DOI] [PubMed] [Google Scholar]
  • 23. Yang D, Nakao M, Shichijo S, Sasatomi T, Takasu H, Matsumoto H, Mori K, Hayashi A, Yamana H, Shirouzu K, Itoh K. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA‐A24‐restricted cytotoxic T lymphocytes in cancer patients. Cancer Res 1999; 59: 4056–63. [PubMed] [Google Scholar]
  • 24. Gomi S, Nakao M, Niiya F, Imamura Y, Kawano K, Nishizaka S, Hayashi A, Sobao Y, Oizumi K, Itoh K. A cyclophilin B gene encodes antigenic epitopes recognized by HLA‐A24‐restricted and tumor‐specific cytotoxic T lymphocytes. J Immunol 1999; 163: 4994–5004. [PubMed] [Google Scholar]
  • 25. Harashima N, Tanaka K, Sasatomi T, Shimizu K, Miyagi Y, Yamada A, Tamura M, Yamana H, Itoh K, Shichijio S. Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T lymphocytes of cancer patients with distant metastases. Eur J Immunol 2000; 31: 323–32. [DOI] [PubMed] [Google Scholar]
  • 26. Nishizaka S, Gomi S, Harada K, Oizumi K, Itoh K, Shichijo S. A new tumor‐rejection antigen recognized by cytotoxic T lymphocytes infiltrating into a lung adenocarcinoma. Cancer Res 2000; 60: 4830–7. [PubMed] [Google Scholar]
  • 27. Kawano K, Gomi S, Tanaka K, Tsuda N, Kamura T, Itoh K, Yamada A. Identification of a new endoplasmic reticulum‐resident protein recognized by HLA‐A24‐restricted tumor infiltrating lymphocytes of lung cancer. Cancer Res 2000; 60: 3550–8. [PubMed] [Google Scholar]
  • 28. Leyland‐Jones B. Trastuzumab: hopes and realities. Lancet Oncol 2002; 3: 137–44. [DOI] [PubMed] [Google Scholar]
  • 29. Rosen LS. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control 2002; 9: 36–44. [DOI] [PubMed] [Google Scholar]
  • 30. Czuczman MS. Immunochemotherapy in indolent non‐Hodgkin's lymphoma. Semin Oncol 2002; 29: 11–7. [DOI] [PubMed] [Google Scholar]
  • 31. Socinski MA, Morris DE, Masters GA, Lilenbaum R. Chemotherapeutic management of stage IV non‐small cell lung cancer. Chest 2003; 123: 226s–43s. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES